May 26th, 2023 (Shanghai) — We are glad to announce that Yongqiang Zhu, the CEO of Nanjing Chuangte, has been invited to present at ACCESS CHINA Boston Forum on June 4th. ACCESS CHINA Biotech Forum is the largest corporate access event between Asia and the western biopharma industry.
Please contact us if you would like to have 1 on 1 meeting with Nanjing Chuangte.
About Nanjing Chuangte
Nanjing Chuangte Pharmaceutical Technology Co., Ltd. was founded in February 2019. The company is an innovative biotech company specializing in research and development of new drugs. With the enterprise mission of “Health for the public, benefit for the world”, Nanjing Chuangte focus on cancers, cardiovascular and respiratory diseases, and are committed to providing innovative products so as to consistently provide patients with health services, and create value for customers.
The company attaches great importance to R&D innovation and talent introduction, with research and management team of around 40 people. 80% of team members hold the Ph.D./master degrees. The company also employed professors, researchers, senior engineers and many scientific consultants.
The pipeline comprises 19 new drugs in development, with 3 new drugs in clinical trials and all drugs are showing satisfactory data in clinical trials.
公司简介
南京创特医药科技有限公司成立于2019年2月，是一家专门从事新药研发、技术转让、医药新产品产业化的创新型生物医药企业。创特医药以人类健康为己任，以科技创新为宗旨，秉承“健康大众、惠泽天下”的企业使命，聚焦肿瘤、脑血管及呼吸系统疾病，致力于提供创新型的产品，通过创新驱动医药产业资源的整合，持续为患者健康服务，为客户创造价值。
公司重视研发创新及人才引进，目前拥有研发及管理人员近40名，80%人员具有博士/硕士学历，拥有教授、研究员、高级工程师3人，科学顾问多人。
通过持续的研发投入和不懈努力，公司目前已建立起包括19个在研药物的产品研发管线，其中3个创新药进入临床阶段，且临床进展顺利。
About the speaker
Dr. Yongqiang Zhu founded Nanjing Chuangte in February 2019 as the CEO, dedicated to the design and research of new drugs. Dr. Zhu has experience in drug research and development for more than 20 years, and has chaired a number of national and provincial major science and technology projects. In total, 16 clinical approvals were obtained for new drugs (including 3 new drugs of category 1), with one new drug in phase III clinical study, and one new drug been approved for clinical trials both by the FDA and NMPA.
Dr. Zhu received the Bachelor’s degree in Chemistry from Sichuan University, Master’s degree in Organic Chemistry from Huazhong University of Science and Technology, and Ph.D. from Peking University. After that, he joined the Pharmaceutical Research Institute of Simcere as director of the Pharmaceutical Chemistry Laboratory. He then joined Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd. Afterwards he worked as a postdoctoral researcher in the University of Michigan in professor Wang Shaomeng’s team.
Dr Zhu has extensive experience in design of targeted drug and research on drug action at the molecular level, as well as management of a corporate.
专家简介
朱永强博士于2019年2月创立南京创特医药科技有限公司，任CEO一职，致力于创新药的设计及研究工作，拥有20余年药物研发经验，曾主持实施多项国家级、省级重大科技项目，目前已获16个新药临床批件（含3个1类新药），其中一项已完成三期临床研究，一项同时在美国FDA和中国NMPA获批临床。
朱永强博士曾获四川大学化学专业学士学位、华中科技大学有机化学专业硕士学位、北京大学药学院博士学位，毕业后加入先声药业药物研究所，任药物化学实验室主任。之后加入江苏正大丰海制药有限公司，任药物研究所所长。后至美国密西根大学医学院肿瘤中心，加入导师王少萌团队，从事博士后研究工作。
朱永强博士深耕于靶点药物设计、分子水平药物作用机制等方面的研究，同时在企业管理及人才培养方面具有丰富经验。
About ACCESS CHINA Boston Forum
“ACCESS CHINA – Boston Forum @BIO” is scheduled to be held on June 4th and June 13th-15th, 2023, in Boston and online, respectively. This event is expected to be the largest Asia-themed gathering during the BIO Convention 2023. The main theme of the forum is “Building Effective Partnerships in Asia: Strategies for Collaboration and Growth”. During the forum, we will cover a range of key topics include drug innovation, market trends, partnership models, and best practices for successful collaborations, etc.
Conference Name: ACCESS CHINA – Boston Forum @BIO
Date & Time: June 4, Sun. (Boston) and June 13-15 (Online)
Content: Keynote Speeches, Panel Discussion, Company Presentations, ChemPartner-ACCESS CHINA Dinner Reception
Scale: Expected 1000 participants Online, 150 participants onsite; 100 company roadshows
Participants: Pharma/Biotech senior management and BDs, investors.
View more information at https://biotochina.org/
关于药通中国-波士顿论坛
“ACCESS CHINA 药通中国-波士顿论坛@BIO”将于2023年6月4-15日在波士顿及线上举行的。此次论坛将是BIO Convention 2023大会期间最大的亚洲主题交流活动。在过去3年时间，药通中国已成功举办13届线上线下活动，帮助近千家公司在药通平台上展出。
大会名称：药通中国-波士顿论坛@BIO
大会日期：2023.6.4（周日，波士顿） 2023.6.13-15（线上）
大会内容：主题演讲、圆桌讨论、海内外优质项目路演、睿智医药-药通中国招待晚宴
大会规模：预计线上1000参会者； 线下150参会者; 100场公司路演
参会观众：海内外医药企业（药企及Biotech）高管及BD、基金高管
查看更多信息： https://biotochina.org/
MORE INFORMATION
Contact US
Register ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum
For more information, please contact:
Wendi Xiang
Wxiang@yafocapital.com
BioToChina.org 